F-star Therapeutics, Inc. (FSTX)
F-star Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, GB. The stock last traded at $7.12, up 0.00% on the session, giving a market capitalisation of $156.5M. On trailing twelve-month figures it carries a trailing P/E of -3.79, a net margin of -147.8%. Its beta of -0.35 implies it has historically moved less than the broad market.
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to inventing tetravalent bispecific antibodies for the treatment of cancer, particularly within the field of immuno-oncology. The company's primary investigational product, FS118, is currently in a Phase 2 proof-of-concept trial, evaluating its efficacy in head and neck cancer patients who have acquired resistance to PD-1/PD-L1 therapies. F-star is also advancing FS222, a bispecific antibody designed to simultaneously target the costimulatory CD137 receptor and the inhibitory PD-L1 ligand, through its initial Phase 1 human clinical study. Moreover, two additional drug candidates, FS120 and SB 11285, are undergoing Phase 1 clinical evaluation for patients with advanced malignancies. Founded in 2002, F-star Therapeutics, Inc. has its corporate headquarters situated in Cambridge, United Kingdom.
F-star Therapeutics, Inc. is most often compared with the following Healthcare names: